WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 523108
Description: JNJ 63533054 is a potent and selective GPR139 agonist (EC50 = 16 nM) that is brain and cell penetrant. JNJ 63533054 is selective for GPR139 over a panel of GPCRs, ion channels and transporters, including GPR142 and is orally bioavailable.
MedKoo Cat#: 523108
Name: JNJ 63533054
Chemical Formula: C17H17ClN2O2
Exact Mass: 316.09786
Molecular Weight: 316.79
Elemental Analysis: C, 64.46; H, 5.41; Cl, 11.19; N, 8.84; O, 10.10
Synonym: JNJ 63533054; JNJ63533054; JNJ-63533054.
IUPAC/Chemical Name: 3-Chloro-N-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]benzamide
InChi Key: MWDVCHRYCKXEBY-LBPRGKRZSA-N
InChi Code: InChI=1S/C17H17ClN2O2/c1-12(13-6-3-2-4-7-13)20-16(21)11-19-17(22)14-8-5-9-15(18)10-14/h2-10,12H,11H2,1H3,(H,19,22)(H,20,21)/t12-/m0/s1
SMILES Code: O=C(NCC(N[C@H](C1=CC=CC=C1)C)=O)C2=CC=CC(Cl)=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
|Biological target:||JNJ 63533054 is a potent and selective GPR139 agonist that specifically activated human GPR139 in the calcium mobilization (EC50 = 16 ± 6 nM) and GTPγS binding (EC50 = 17 ± 4 nM) assays.|
|In vitro activity:||JNJ-63533054 specifically activated human GPR139 in the calcium mobilization (EC50 = 16 ± 6 nM) and GTPγS binding (EC50 = 17 ± 4 nM) assays. JNJ-63533054 also activated the rat and mouse GPR139 receptor with similar potency (rat EC50 = 63 ± 24 nM, mouse EC50 = 28 ± 7 nM). Addition of a low concentration of NaCl and divalent ions did not shift the affinity of the tracer for GPR139 (data not shown). On membranes from T-Rex CHO cells expressing human GPR139, a high signal-to-noise ratio was observed (total versus nonspecific binding P < 0.0001), and no specific binding was detected in membranes from noninduced human GPR139 cells or control membranes from untransfected cells (Fig. 5B). In a saturation study for human GPR139, a single population of high-affinity binding sites for [3H] JNJ-63533054 was observed, and the Kd (10 ± 3 nM) was in agreement with the corresponding EC50 (Fig. 5C). The Bmax value was 26 ± 4 pmol/mg of protein. Saturation studies for the rat GPR139 and mouse GPR139 yielded Kd values within the same range (32 ± 13 nM and 23 ± 4 nM, respectively; Bmax = 8.5 ± 2.5pmol/mg of protein and 6.2 ± 1.6pmol/mg of protein, respectively). Reference: Mol Pharmacol. 2015 Nov;88(5):911-25. http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=26349500|
|In vivo activity:||The aim of this study was to characterize a selective and brain penetrant GPR139 agonist (JNJ-63533054) in relevant in vivo models. JNJ-63533054 was tested for its effect on c-fos activation in the habenula and dorsal striatum. In vivo microdialysis experiments were performed in freely moving rats to measure basal levels of serotonin or dopamine (DA) in prefrontal cortex (mPFC) and nucleus accumbens (NAc). Finally, the compound was profiled in behavioral models of anxiety, despair, and anhedonia. The agonist (10-30 mg/kg, p.o.) did not alter c-fos expression in medial habenula or dorsal striatum nor neurotransmitter levels in mPFC or NAc. JNJ-63533054 (10 mg/kg p.o.) produced an anhedonic-like effect on urine sniffing, but had no significant effect in tail suspension, with no interaction with imipramine, no effect on naloxone place aversion, and no effect on learned helplessness. In the marble burying test, the agonist (10 mg/kg p.o.) produced a small anxiolytic-like effect, with no interaction with fluoxetine, and no effect in elevated plus maze (EPM). Despite GPR139 high expression in medial habenula, an area with connections to limbic and catecholaminergic/serotoninergic areas, the GPR139 agonist had no effect on c-fos in medial habenula. It did not alter catecholamine/serotonin levels and had a mostly silent signal in in vivo models commonly associated with these pathways. Reference: Front Pharmacol. 2019 Mar 21;10:273. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30949055/|
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 316.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
|In vitro protocol:||1. Nepomuceno D, Kuei C, Dvorak C, Lovenberg T, Liu C, Bonaventure P. Re-evaluation of Adrenocorticotropic Hormone and Melanocyte Stimulating Hormone Activation of GPR139 in Vitro. Front Pharmacol. 2018 Mar 2;9:157. doi: 10.3389/fphar.2018.00157. PMID: 29599718; PMCID: PMC5863515.|
|In vivo protocol:||1. Shoblock JR, Welty N, Fraser I, Wyatt R, Lord B, Lovenberg T, Liu C, Bonaventure P. In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist. Front Pharmacol. 2019 Mar 21;10:273. doi: 10.3389/fphar.2019.00273. PMID: 30949055; PMCID: PMC6437111.|
1: Liu C, Bonaventure P, Lee G, Nepomuceno D, Kuei C, Wu J, Li Q, Joseph V, Sutton SW, Eckert W, Yao X, Yieh L, Dvorak C, Carruthers N, Coate H, Yun S, Dugovic C, Harrington A, Lovenberg TW. GPR139, an Orphan Receptor Highly Enriched in the Habenula and Septum, Is Activated by the Essential Amino Acids L-Tryptophan and L-Phenylalanine. Mol Pharmacol. 2015 Nov;88(5):911-25. doi: 10.1124/mol.115.100412. Epub 2015 Sep 8. PubMed PMID: 26349500.